• Latest Posts

AI program finds multiple influenza drug targets

Poolbeg expands POLB 001 into oncology

Poolbeg identifies new potential drug candidates for RSV infections 

Poolbeg influenza trial successfully completed

Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform

AI program yields multiple novel RSV drug targets


Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments